Clinical Report: International Outsourcing of Molecular Diagnostics for CNS Tumors

Background

Molecular profiling is essential for the diagnosis and treatment of CNS tumors, particularly following the WHO CNS5 classification. However, access to these diagnostics is limited in low-resource settings, necessitating alternative strategies such as international outsourcing.

Data Highlights

Key Findings

• 92% of samples yielded conclusive molecular results.
• Median turnaround time for testing was 26 days.
• Actionable therapeutic targets were identified in 27% of tumors.
• Molecular testing led to a change in diagnosis in 4% of cases.
• Highest conclusive result rate was in medulloblastoma (94%).
• Lowest conclusive result rate was in ependymoma (33%).

Clinical Implications

This study provides insights into the potential of outsourcing molecular diagnostics in low-resource settings.

Conclusion

The study demonstrates that international outsourcing of molecular diagnostics is a viable strategy for CNS tumor management in resource-limited settings.

Related Resources & Content

1. Acta Neuropathologica, 2024 -- Accelerated Diagnosis of Brain Lymphoma via Nanopore Sequencing of Cytology-Negative Cerebrospinal Fluid
2. Journal of Neuro-Oncology, 2022 -- Targeted Molecular Therapies for Primary Brain Tumors: A Retrospective Study from a Single Institution
3. Acta Neuropathologica, 2024 -- Identification of H3F3A K27M or BRAF V600E in Liquid Biopsies for Brain Tumor Patients: Diagnostic and Monitoring Implications Considering Tumor Location and Sampling Techniques
4. Journal of Neuro-Oncology, 2024 -- Evaluation of Next-Generation Sequencing in High-Grade Adult-Type Diffuse Gliomas Across Dutch Laboratories: Variability in Initial and Recurrence Diagnoses
5. NCCN CNS Tumor Guidelines Update for 2024 - PMC
6. NCCN CNS Tumor Guidelines Update for 2025
7. NCCN CNS Tumor Guidelines Update for 2024 - PMC